DK1346036T3 - Virusfri virusamplicon hjælpepartikler samt anvendelser deraf - Google Patents

Virusfri virusamplicon hjælpepartikler samt anvendelser deraf

Info

Publication number
DK1346036T3
DK1346036T3 DK01994201.0T DK01994201T DK1346036T3 DK 1346036 T3 DK1346036 T3 DK 1346036T3 DK 01994201 T DK01994201 T DK 01994201T DK 1346036 T3 DK1346036 T3 DK 1346036T3
Authority
DK
Denmark
Prior art keywords
methods
virus
particles
free
those
Prior art date
Application number
DK01994201.0T
Other languages
English (en)
Inventor
Khaled A Tolba
Richard A Willis
Thomas J Evans
Peter K Hocknell
Joseph D Rosenblatt
Howard J Federoff
William J Bowers
John G Frelinger
Stephen Dewhurst
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester filed Critical Univ Rochester
Application granted granted Critical
Publication of DK1346036T3 publication Critical patent/DK1346036T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK01994201.0T 2000-11-29 2001-11-29 Virusfri virusamplicon hjælpepartikler samt anvendelser deraf DK1346036T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25385800P 2000-11-29 2000-11-29
US25007900P 2000-11-30 2000-11-30
PCT/US2001/047808 WO2002056828A2 (en) 2000-11-29 2001-11-29 Helper virus-free herpes virus amplicon particles and uses thereof

Publications (1)

Publication Number Publication Date
DK1346036T3 true DK1346036T3 (da) 2010-07-19

Family

ID=26940582

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01994201.0T DK1346036T3 (da) 2000-11-29 2001-11-29 Virusfri virusamplicon hjælpepartikler samt anvendelser deraf

Country Status (8)

Country Link
US (2) US20030027322A1 (da)
EP (1) EP1346036B1 (da)
AT (1) ATE466078T1 (da)
AU (1) AU2002246625B2 (da)
CA (1) CA2430589A1 (da)
DE (1) DE60141976D1 (da)
DK (1) DK1346036T3 (da)
WO (1) WO2002056828A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430589A1 (en) 2000-11-29 2002-07-25 University Of Rochester Helper virus-free herpes virus amplicon particles and uses thereof
US8092791B2 (en) 2001-05-23 2012-01-10 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
ATE414176T1 (de) * 2002-07-18 2008-11-15 Univ Washington Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene
CA2513559A1 (en) * 2003-01-23 2004-08-05 University Of Rochester Herpesvirus amplicon particles
US20040229362A1 (en) * 2003-05-15 2004-11-18 Alberto Epstein Method for producing non-pathogenic helper virus-free preparations of herpes virus amplicon vectors, the helper virus & the cells used in this method, the corresponding genetic tools, as well as the applications of these non-pathogenic amplicon vectors
US7595306B2 (en) * 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
EP1635763B1 (en) * 2003-06-09 2012-08-08 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
US20070264281A1 (en) * 2003-08-04 2007-11-15 Niza Frenkel Vaccination Vectors Derived From Lymphotropic Human Herpes Viruses 6 and 7
WO2005046605A2 (en) * 2003-11-07 2005-05-26 University Of Rochester Compositions and methods of treating neurological diseases
GB0409596D0 (en) * 2004-04-29 2004-06-02 Crusade Lab Ltd Novel herpes simplex viruses and uses thereof
US20080226677A1 (en) * 2004-05-06 2008-09-18 Yasuko Mori Recombinant virus vector for gene transfer into lymphoid cells
US20070166316A1 (en) 2004-09-11 2007-07-19 Mosca Joseph D Tumor-derived biological antigen presenting particles
US7496565B2 (en) * 2004-11-30 2009-02-24 Microsoft Corporation Method and system for maintaining namespace consistency with a file system
WO2007143681A2 (en) * 2006-06-06 2007-12-13 University Of Rochester Helper virus-free herpesvirus amplicon particles and uses thereof
EP2125032A4 (en) 2007-02-20 2011-02-23 Mayo Foundation TREATMENT OF CANCER USING VIRAL NUCLEIC ACID
US20110123485A1 (en) * 2007-03-27 2011-05-26 President And Fellows Of Harvard College Viral vectors for delivering vaccines for hiv and other infectious diseases
CN109337874B (zh) * 2018-12-10 2020-05-12 畜科生物工程有限公司 一种重组猪伪狂犬病毒及其应用和重组猪伪狂犬病活疫苗

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2045129A1 (en) 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
ATE192499T1 (de) 1992-03-13 2000-05-15 Monsanto Co Herstellung rekombinanter proteine unter verwendung von herpes-virus-promotoren und vp16- transaktivatoren
US5804413A (en) * 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US6040172A (en) 1992-08-14 2000-03-21 The Rockefeller University Defective DNA viral vector comprising a neural tissue-specific promoter for in vivo expression of a gene
US5661033A (en) * 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
US5763217A (en) 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
WO1996029421A1 (en) 1995-03-23 1996-09-26 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
WO1997000085A1 (en) 1995-06-19 1997-01-03 University Of Medicine & Dentistry Of New Jersey Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins
US5851826A (en) * 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
US6344445B1 (en) * 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
US5965441A (en) 1996-11-13 1999-10-12 The General Hospital Coporation HSV/AAV hybrid amplicon vectors
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
GB9816856D0 (en) 1998-08-03 1998-09-30 Univ London Cell lines for virus growth
EP1153136A2 (en) * 1998-12-09 2001-11-14 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
CN1140626C (zh) 1999-10-27 2004-03-03 本元正阳基因技术股份有限公司 一种重组i型单纯疱疹病毒及其用途
WO2001030965A2 (en) * 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
DE10120829A1 (de) * 2000-04-27 2001-12-20 Max Delbrueck Centrum Sleeping Beauty, ein Transposonvektor mit breitem Wirtsbereich für die genetische Transformation bei Wirbeltieren
CA2410536A1 (en) 2000-05-23 2001-11-29 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
CA2430589A1 (en) 2000-11-29 2002-07-25 University Of Rochester Helper virus-free herpes virus amplicon particles and uses thereof
WO2002053576A1 (en) 2001-01-05 2002-07-11 The General Hospital Corporation Viral delivery system for infectious transfer of large genomic dna inserts
JP2004529158A (ja) 2001-05-02 2004-09-24 ラモツト・アツト・テル−アビブ・ユニバーシテイ・リミテツド 混成殺腫瘍ヘルペスウイルスベクター

Also Published As

Publication number Publication date
US20060204477A1 (en) 2006-09-14
AU2002246625B2 (en) 2008-01-10
DE60141976D1 (de) 2010-06-10
US8119118B2 (en) 2012-02-21
EP1346036A4 (en) 2006-04-19
CA2430589A1 (en) 2002-07-25
WO2002056828A3 (en) 2002-10-03
EP1346036B1 (en) 2010-04-28
WO2002056828A2 (en) 2002-07-25
EP1346036A2 (en) 2003-09-24
ATE466078T1 (de) 2010-05-15
US20030027322A1 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
DK1346036T3 (da) Virusfri virusamplicon hjælpepartikler samt anvendelser deraf
IL157504A0 (en) Oncolytic virus therapy
BRPI0417512B8 (pt) peça de vestuário absorvente descartável
DE69233186D1 (de) Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
NZ215939A (en) Phosphonyl methoxyadenine antiviral compositions
KR970704410A (ko) 암 치료용 종양 세포를 함유하는 이식 장치(Implanted Device Containing Tumor Cells for the Treatment of Cancer)
WO2003101396A3 (en) Helper virus-free herpesvirus amplicon particles and uses thereof
MXPA05012319A (es) Suministro de compuestos con celulas sanguineas rehidratadas.
MX2022014433A (es) Metodos para minimizar el riesgo de transmision de infecciones.
AR042530A1 (es) Vacuna que comprende particulas viroides del virus papiloma humano 16 y 18
BR9901609A (pt) Artigo absorvente descartável de fluìdos corporais.
WO2007143681A3 (en) Helper virus-free herpesvirus amplicon particles and uses thereof
CO5180599A1 (es) Producto absorbente respirable y metodo para producir dicho producto
JP2017008105A (ja) 癌の処置のための粘液腫ウイルス変異体
OA09653A (en) Rubella peptides
HK1055462A1 (en) Identification of viral agents in breast ducts andantiviral therapy therefore
Storozynsky et al. Radiation-induced cellular senescence reduces susceptibility of glioblastoma cells to oncolytic vaccinia virus
ZA968783B (en) Flupirtine usage
AR034384A1 (es) Un articulo absorbente
DE69807129D1 (de) Verwendung einer Kombination von beta-Sitosterol und beta-Sitosterol-Glukosid zur Herstellung eines Medikamentes zur Behandlung von HIV-Infektion
Biedunkiewicz et al. Natural killer cell activity unaffected by ozonated autohemotherapy in patients with end-stage renal disease on maintenance renal replacement therapy
ES2168583T3 (es) Parasitos que infectan macrofagos que expresan un factor que estimula colonias de macrofagos granulociticos.
CN213158117U (zh) 一种内科护理用的吸痰护理箱
ES2087199T3 (es) Vacunas contra virus de herpes equino y su fabricacion.
Ayeni et al. Some new results on affinity hemodialysis and T cell recovery